Neal L. Benowitz
University of California, San Francisco
826 Papers
9K Citations
Neal L. Benowitz is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Nicotine & Cotinine. The author has an hindex of 126, co-authored 792 publications. Previous affiliations of Neal L. Benowitz include Shaare Zedek Medical Center & University College London.
Chat about Author
Papers
Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.
TL;DR: Toxicity is very common with class 1B antiarrhythmic drugs and can be life-threatening, but serious toxicity can be prevented by close clinical surveillance and appropriate dose reduction in patients with reduced drug clearance.
Dual Users Compared to Smokers: Demographics, Dependence, and Biomarkers
TL;DR: A comparison of a community sample of established dual users and exclusive smokers addresses key questions of dependence and health risks of dual use in real-world settings, suggesting that dual users are supplementing their smoking with e-cigarette use.
Relationships Between Race, Gender, and Spot Urine Levels of Biomarkers of Tobacco Exposure Vary Based on How Creatinine Is Handled in Analyses.
Dana M. Carroll,Shannon S. Cigan,Joshua Ikuemonisan,Taylor Hammonds,Irina Stepanov,Gideon St.Helen,Neal L. Benowitz,Dorothy K. Hatsukami +7 more
TL;DR: The differential impact of common analysis approaches to handling urinary creatinine, a measure for urine dilution, on relationships between race, gender, and biomarkers of exposure (BOE) measured in spot urine is illustrated.
Clinical significance of early smoking withdrawal effects and their relationships with nicotine metabolism: preliminary results from a pilot study.
TL;DR: Findings lend support to the clinical significance of early smoking withdrawal effects and suggest the rate of nicotine metabolism may be a useful predictor of early withdrawal symptoms.
Safety of intra-amniotic digoxin administration before late second-trimester abortion by dilation and evacuation.
TL;DR: On the basis of the limited systemic absorption and the absence of clinically significant cardiac or clotting effects, intra-amniotically administered digoxin may be considered safe for use before late second-trimester pregnancy terminations.